Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

113 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia.
Caruso S, De Angelis B, Del Bufalo F, Ciccone R, Donsante S, Volpe G, Manni S, Guercio M, Pezzella M, Iaffaldano L, Silvestris DA, Sinibaldi M, Di Cecca S, Pitisci A, Velardi E, Merli P, Algeri M, Lodi M, Paganelli V, Serafini M, Riminucci M, Locatelli F, Quintarelli C. Caruso S, et al. Among authors: pezzella m. J Hematol Oncol. 2022 Nov 5;15(1):163. doi: 10.1186/s13045-022-01376-3. J Hematol Oncol. 2022. PMID: 36335396 Free PMC article.
Spermine oxidase induces DNA damage and sensitizes fusion negative rhabdomyosarcoma cells to irradiation.
Perrone C, Pomella S, Cassandri M, Pezzella M, Giuliani S, Gasperi T, Porrazzo A, Alisi A, Pastore A, Codenotti S, Fanzani A, Barillari G, Conti LA, De Angelis B, Quintarelli C, Mariottini P, Locatelli F, Marampon F, Rota R, Cervelli M. Perrone C, et al. Among authors: pezzella m. Front Cell Dev Biol. 2023 Jan 23;11:1061570. doi: 10.3389/fcell.2023.1061570. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 36755974 Free PMC article.
Neutralizing IFNγ improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies.
Manni S, Del Bufalo F, Merli P, Silvestris DA, Guercio M, Caruso S, Reddel S, Iaffaldano L, Pezzella M, Di Cecca S, Sinibaldi M, Ottaviani A, Quadraccia MC, Aurigemma M, Sarcinelli A, Ciccone R, Abbaszadeh Z, Ceccarelli M, De Vito R, Lodi MC, Cefalo MG, Mastronuzzi A, De Angelis B, Locatelli F, Quintarelli C. Manni S, et al. Among authors: pezzella m. Nat Commun. 2023 Jun 9;14(1):3423. doi: 10.1038/s41467-023-38723-y. Nat Commun. 2023. PMID: 37296093 Free PMC article.
MYOD-SKP2 axis boosts tumorigenesis in fusion negative rhabdomyosarcoma by preventing differentiation through p57Kip2 targeting.
Pomella S, Cassandri M, D'Archivio L, Porrazzo A, Cossetti C, Phelps D, Perrone C, Pezzella M, Cardinale A, Wachtel M, Aloisi S, Milewski D, Colletti M, Sreenivas P, Walters ZS, Barillari G, Di Giannatale A, Milano GM, De Stefanis C, Alaggio R, Rodriguez-Rodriguez S, Carlesso N, Vakoc CR, Velardi E, Schafer BW, Guccione E, Gatz SA, Wasti A, Yohe M, Ignatius M, Quintarelli C, Shipley J, Miele L, Khan J, Houghton PJ, Marampon F, Gryder BE, De Angelis B, Locatelli F, Rota R. Pomella S, et al. Among authors: pezzella m. Nat Commun. 2023 Dec 15;14(1):8373. doi: 10.1038/s41467-023-44130-0. Nat Commun. 2023. PMID: 38102140 Free PMC article.
GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma.
Ciccone R, Quintarelli C, Camera A, Pezzella M, Caruso S, Manni S, Ottaviani A, Guercio M, Del Bufalo F, Quadraccia MC, Orlando D, Di Cecca S, Sinibaldi M, Aurigemma M, Iaffaldano L, Sarcinelli A, D'Amore ML, Ceccarelli M, Nazio F, Marabitti V, Giorda E, Pezzullo M, De Stefanis C, Carai A, Rossi S, Alaggio R, Del Baldo G, Becilli M, Mastronuzzi A, De Angelis B, Locatelli F. Ciccone R, et al. Among authors: pezzella m. Clin Cancer Res. 2024 Jun 3;30(11):2545-2557. doi: 10.1158/1078-0432.CCR-23-1880. Clin Cancer Res. 2024. PMID: 38551501 Free PMC article.
Tumor-derived G-CSF induces an immunosuppressive microenvironment in an osteosarcoma model, reducing response to CAR.GD2 T-cells.
Pezzella M, Quintarelli C, Quadraccia MC, Sarcinelli A, Manni S, Iaffaldano L, Ottaviani A, Ciccone R, Camera A, D'Amore ML, Di Cecca S, Sinibaldi M, Guercio M, Aurigemma M, De Falco P, Fustaino V, Rota R, Pomella S, Cassandri M, Di Giannatale A, Agrati C, Bordoni V, Guarracino F, Massa M, Del Baldo G, Becilli M, Milano GM, Del Bufalo F, Locatelli F, De Angelis B. Pezzella M, et al. J Hematol Oncol. 2024 Dec 18;17(1):127. doi: 10.1186/s13045-024-01641-7. J Hematol Oncol. 2024. PMID: 39695851 Free PMC article.
Adjunctive brivaracetam and sustained seizure frequency reduction in very active focal epilepsy.
Lattanzi S, Canafoglia L, Canevini MP, Casciato S, Cerulli Irelli E, Chiesa V, Dainese F, De Maria G, Didato G, Di Gennaro G, Falcicchio G, Fanella M, Ferlazzo E, Gangitano M, La Neve A, Mecarelli O, Montalenti E, Morano A, Piazza F, Pizzanelli C, Pulitano P, Ranzato F, Rosati E, Tassi L, Di Bonaventura C; BRIVAFIRST (Brivaracetam Add‐On First Italian Network Study) Group Membership. Lattanzi S, et al. Epilepsia. 2023 Nov;64(11):2922-2933. doi: 10.1111/epi.17740. Epub 2023 Sep 9. Epilepsia. 2023. PMID: 38079181 Free article.
113 results